Stocktoria
LianBio LIANY
OTC · stock · Pharmaceutical Preparations · website · IPO 2021-10-28
LianBio financials (annual, from 10-K)
Bars are annual figures from 2020 to 2022; red bars are negative (a loss or cash outflow).
| Metric | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| R&D expense | $59.8M | $158.7M | $120.9M |
| Operating income | -$125.4M | -$195.6M | -$134.9M |
| Income tax | -$333,000 | $518,000 | $4,000 |
| Net income | -$110.3M | -$196.3M | -$139.6M |
| EPS (diluted) | $-1.02 | $-5.71 | $-11.58 |
| Operating cash flow | -$99.2M | -$164.0M | -$98.1M |
| Free cash flow | -$101.0M | -$164.9M | -$99.0M |
| Cash & equivalents | $79.2M | $228.2M | $254.3M |
| Total assets | $320.0M | $426.3M | $279.3M |
| Total liabilities | $26.3M | $39.0M | $27.6M |
| Shareholders' equity | $293.6M | $387.3M | -$132.8M |
Source: SEC EDGAR filings · CIK 0001831283 · US · as of 2022-12-31. facts plus Stocktoria's own computed scores — not investment advice.